Navigation Links
Alfacell Announces Receipt of NASDAQ Panel Decision
Date:1/5/2009

SOMERSET, N.J., Jan. 5 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that it received notification on January 2, 2009 that the NASDAQ Listing Qualifications Panel has determined to delist the Company's securities from The NASDAQ Stock Market, effective with the open of business on Tuesday, January 6, 2009. The delisting is the result of the Company's non-compliance with the $35 million market value of listed securities requirement and its alternatives for continued listing on The NASDAQ Capital Market.

The Company has been advised that its securities are immediately eligible for quotation in the Pink Sheets, an electronic quotation service for securities traded over-the-counter, effective with the open of business on January 6, 2009. The Company's shares will continue to trade under the symbol ACEL. The Company's common stock may, in the future, also be quoted on the Over-the-Counter Bulletin Board (the "OTCBB"), an electronic quotation service maintained by the Financial Industry Regulatory Authority (or FINRA), provided that a market maker in the Company's common stock files the appropriate application with, and such application is cleared by, FINRA. The Company anticipates disclosing further trading venue information for its common stock once such information becomes available.

The Company has the right to request that the NASDAQ Listing and Hearing Review Panel review this decision and the Company may pursue this right. If the Company pursues this right of review, the decision to delist the Company's securities from The NASDAQ Stock Market will not be stayed while such review is pending.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. For more information, visit www.alfacell.com.

About Pink Sheets LLC

Pink Sheets' centralized information network is a source of competitive market maker quotations, historical prices and corporate information about OTC issues and issuers. Pink Sheets is neither an SEC-Registered Stock Exchange nor a Broker-Dealer. Investors should contact a Broker-Dealer to trade in a security quoted on the Pink Sheets. More information is available at http://www.pinksheets.com.

About the OTCBB

The OTCBB is a regulated quotation service that displays real-time quotes, last-sale prices, and volume information in OTC equity securities. An OTC equity security generally is any equity that is not listed or traded on a national securities exchange. OTCBB securities include national, regional, and foreign equity issues, warrants, units, ADRs, and Direct Participation Programs. More information is available at http://www.otcbb.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainty whether the clinical trial results will allow the company to complete submission of a New Drug Application and if a New Drug Application submission is completed, uncertainty whether FDA will file or approve such application, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials or differences of opinion in interpreting the results of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, uncertainties involving whether and when any over-the-counter stock trading market will accept the Company's securities for trading, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    Media Contact:                      Investor Contact:
    David Schull or Wendy Lau           Andreas Marathovouniotis
    Russo Partners                      Russo Partners
    212-845-4271                        212-845-4253
    David.Schull@russopartnersllc.com   Andreas.Marathis@russopartnersllc.com
    Wendy.Lau@russopartnersllc.com


'/>"/>
SOURCE Alfacell Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Alfacell Announces Management Update
2. Alfacell Reports Financial Results for First Quarter of Fiscal 2009
3. Alfacell to Host Fiscal First Quarter 2008 Financial Results Conference Call and Webcast
4. Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
5. Go Ask Alice ... Nationally Recognized Life Coach & Psychotherapist, Alice Donavin, LCSW Announces the Implementation of Office/House Calls to her Newly Launched Philadelphia Practice
6. Mobile Massage Team Announces Eleven New Therapist Members in the Northeast U.S. Region
7. Misonix Announces New HIFU Distribution Agreement for Italy
8. Four Rivers Software Systems Announces Integration with ePartsFinder from PartsSource
9. Summa Health Network Announces Contract with MDdatacor to Support Multi-Insurer Health Care Quality Initiative; Initiative to Use Clinical Data to Supplement Claims Data and Enhance Outcomes
10. Dialysis Corporation of America Announces Acquisition of Maryland Dialysis Center
11. SXC Health Solutions announces contract with PharMerica
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... in Wethersfield, Conn., has relocated its corporate headquarters to a new, more expansive ... , In October 2016, Qualidigm purchased a distressed office building in Wethersfield, ...
(Date:3/28/2017)... Billerica, MA (PRWEB) , ... March 28, 2017 ... ... instrument for direct measurement of corrosive ions found in power plant water and ... plant components such as turbines and boilers, leading to extensive maintenance and unplanned ...
(Date:3/28/2017)... ... , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in Ohio ... country to sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics National ... helped propel the clinic from a small start-up to number 78 in the country ...
(Date:3/28/2017)... ... 28, 2017 , ... Prominant bariatric surgeon and well-known weight-loss ... offer the recently FDA-approved Obalon Balloon System to his patients. The Obalon is ... already comprehensive list of weight-loss services. Dr. Liu is proud to announce ...
(Date:3/28/2017)... ... March 28, 2017 , ... With expansion and efficiency in ... early March. , The seed processing plant opened in Marshallville in 2006, and a ... new office allows opportunity for transition of Patten Seed operations to the Middle Georgia ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 28, 2017 The U.S. Food and ... treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent ... controlled adequately by topical therapies, or those for ... be used with or without topical corticosteroids. ... to approving new and innovative therapies for patients ...
(Date:3/28/2017)... PHOENIX , March 28, 2017  Today, ... Pharmacy released a new white paper to ... use of latex in healthcare. Specifically, there is substantial confusion ... fact, the FDA has urged manufacturers to drop the term ... labels, because of the challenge to ensure a product is ...
(Date:3/28/2017)... March 28, 2017 The global ... landscape, with the top three companies, namely Shimadzu Corporation, ... a significant 49% of the overall market in 2015, ... vendor landscape is intensely competitive and has few players, ... market. These factors have restricted the entry of new ...
Breaking Medicine Technology: